Han Yan1, Veda Zabih2, Ute Bartels2, Sunit Das3, Paul Nathan1, Sumit Gupta1. 1. Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. 2. Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada. 3. Division of Neurosurgery, St. Michael's Hospital, University of Toronto, Toronto, OntarioCanada.
Abstract
Background: Medulloblastoma is a rare diagnosis among adolescents and young adults (AYA). Though prognostic factors and treatment are well characterized among children with medulloblastoma, equivalent data for AYA are sparse. We conducted a systematic review to identify predictors of survival among AYA with medulloblastoma. Methods: We searched for primary studies of AYA (age 15-39 at diagnosis) with medulloblastoma in high-income countries within OVID MEDLINE, EMBASE, and EBM Reviews-Cochrane library databases from inception to August 2020. Patient demographics, primary outcomes, and univariate and multivariable data on all prognostic factors were collected from included studies. Prognosticators were characterized as patient, disease, or treatment-related. Results: We identified 18 articles. 5-year overall survival ranged between 40% and 89%, while disease-free survival ranged from 49% to 89%. Study quality was low as assessed by the Quality in Prognostic factor Studies tool. Though meta-analyses were not possible due heterogeneity, narrative summaries suggested that lower disease burden, superior postoperative functional status, and higher doses and larger fields of radiation were associated with improved survival. Reported chemotherapy regimens were heterogeneous in timing, agents, and relationship with radiation, precluding meaningful comparisons. Only one study included molecular subgroups for analysis, with the majority (76.5%) of tumors classified as Sonic Hedgehog (SHH). Conclusions: Prognostication and treatment of AYA medulloblastoma is limited by a dearth of primary evidence and lack of specificity for patients aged 15-39. Dedicated prospective trials to delineate the benefit of various chemotherapy and radiation regimens are required in this population to identify prognosticators and ideal treatment regimens.
Background: Medulloblastoma is a rare diagnosis among adolescents and young adults (AYA). Though prognostic factors and treatment are well characterized among children with medulloblastoma, equivalent data for AYA are sparse. We conducted a systematic review to identify predictors of survival among AYA with medulloblastoma. Methods: We searched for primary studies of AYA (age 15-39 at diagnosis) with medulloblastoma in high-income countries within OVID MEDLINE, EMBASE, and EBM Reviews-Cochrane library databases from inception to August 2020. Patient demographics, primary outcomes, and univariate and multivariable data on all prognostic factors were collected from included studies. Prognosticators were characterized as patient, disease, or treatment-related. Results: We identified 18 articles. 5-year overall survival ranged between 40% and 89%, while disease-free survival ranged from 49% to 89%. Study quality was low as assessed by the Quality in Prognostic factor Studies tool. Though meta-analyses were not possible due heterogeneity, narrative summaries suggested that lower disease burden, superior postoperative functional status, and higher doses and larger fields of radiation were associated with improved survival. Reported chemotherapy regimens were heterogeneous in timing, agents, and relationship with radiation, precluding meaningful comparisons. Only one study included molecular subgroups for analysis, with the majority (76.5%) of tumors classified as Sonic Hedgehog (SHH). Conclusions: Prognostication and treatment of AYA medulloblastoma is limited by a dearth of primary evidence and lack of specificity for patients aged 15-39. Dedicated prospective trials to delineate the benefit of various chemotherapy and radiation regimens are required in this population to identify prognosticators and ideal treatment regimens.
Authors: R D Riley; S A Burchill; K R Abrams; D Heney; P C Lambert; D R Jones; A J Sutton; B Young; A J Wailoo; I J Lewis Journal: Health Technol Assess Date: 2003 Impact factor: 4.014
Authors: Ulrich Herrlinger; A Steinbrecher; J Rieger; P Hau; R-D Kortmann; R Meyermann; M Schabet; M Bamberg; J Dichgans; U Bogdahn; M Weller Journal: J Neurol Date: 2005-02-23 Impact factor: 4.849
Authors: Paul A Northcott; Thomas Hielscher; Adrian Dubuc; Stephen Mack; David Shih; Marc Remke; Hani Al-Halabi; Steffen Albrecht; Nada Jabado; Charles G Eberhart; Wieslawa Grajkowska; William A Weiss; Steven C Clifford; Eric Bouffet; James T Rutka; Andrey Korshunov; Stefan Pfister; Michael D Taylor Journal: Acta Neuropathol Date: 2011-06-17 Impact factor: 17.088
Authors: Marcel Kool; David T W Jones; Natalie Jäger; Paul A Northcott; Trevor J Pugh; Volker Hovestadt; Rosario M Piro; L Adriana Esparza; Shirley L Markant; Marc Remke; Till Milde; Franck Bourdeaut; Marina Ryzhova; Dominik Sturm; Elke Pfaff; Sebastian Stark; Sonja Hutter; Huriye Seker-Cin; Pascal Johann; Sebastian Bender; Christin Schmidt; Tobias Rausch; David Shih; Jüri Reimand; Laura Sieber; Andrea Wittmann; Linda Linke; Hendrik Witt; Ursula D Weber; Marc Zapatka; Rainer König; Rameen Beroukhim; Guillaume Bergthold; Peter van Sluis; Richard Volckmann; Jan Koster; Rogier Versteeg; Sabine Schmidt; Stephan Wolf; Chris Lawerenz; Cynthia C Bartholomae; Christof von Kalle; Andreas Unterberg; Christel Herold-Mende; Silvia Hofer; Andreas E Kulozik; Andreas von Deimling; Wolfram Scheurlen; Jörg Felsberg; Guido Reifenberger; Martin Hasselblatt; John R Crawford; Gerald A Grant; Nada Jabado; Arie Perry; Cynthia Cowdrey; Sydney Croul; Gelareh Zadeh; Jan O Korbel; Francois Doz; Olivier Delattre; Gary D Bader; Martin G McCabe; V Peter Collins; Mark W Kieran; Yoon-Jae Cho; Scott L Pomeroy; Olaf Witt; Benedikt Brors; Michael D Taylor; Ulrich Schüller; Andrey Korshunov; Roland Eils; Robert J Wechsler-Reya; Peter Lichter; Stefan M Pfister Journal: Cancer Cell Date: 2014-03-17 Impact factor: 31.743
Authors: Jill A Hayden; Danielle A van der Windt; Jennifer L Cartwright; Pierre Côté; Claire Bombardier Journal: Ann Intern Med Date: 2013-02-19 Impact factor: 25.391
Authors: Eric M Thompson; Thomas Hielscher; Eric Bouffet; Marc Remke; Betty Luu; Sridharan Gururangan; Roger E McLendon; Darell D Bigner; Eric S Lipp; Sebastien Perreault; Yoon-Jae Cho; Gerald Grant; Seung-Ki Kim; Ji Yeoun Lee; Amulya A Nageswara Rao; Caterina Giannini; Kay Ka Wai Li; Ho-Keung Ng; Yu Yao; Toshihiro Kumabe; Teiji Tominaga; Wieslawa A Grajkowska; Marta Perek-Polnik; David C Y Low; Wan Tew Seow; Kenneth T E Chang; Jaume Mora; Ian F Pollack; Ronald L Hamilton; Sarah Leary; Andrew S Moore; Wendy J Ingram; Andrew R Hallahan; Anne Jouvet; Michelle Fèvre-Montange; Alexandre Vasiljevic; Cecile Faure-Conter; Tomoko Shofuda; Naoki Kagawa; Naoya Hashimoto; Nada Jabado; Alexander G Weil; Tenzin Gayden; Takafumi Wataya; Tarek Shalaby; Michael Grotzer; Karel Zitterbart; Jaroslav Sterba; Leos Kren; Tibor Hortobágyi; Almos Klekner; Bognár László; Tímea Pócza; Peter Hauser; Ulrich Schüller; Shin Jung; Woo-Youl Jang; Pim J French; Johan M Kros; Marie-Lise C van Veelen; Luca Massimi; Jeffrey R Leonard; Joshua B Rubin; Rajeev Vibhakar; Lola B Chambless; Michael K Cooper; Reid C Thompson; Claudia C Faria; Alice Carvalho; Sofia Nunes; José Pimentel; Xing Fan; Karin M Muraszko; Enrique López-Aguilar; David Lyden; Livia Garzia; David J H Shih; Noriyuki Kijima; Christian Schneider; Jennifer Adamski; Paul A Northcott; Marcel Kool; David T W Jones; Jennifer A Chan; Ana Nikolic; Maria Luisa Garre; Erwin G Van Meir; Satoru Osuka; Jeffrey J Olson; Arman Jahangiri; Brandyn A Castro; Nalin Gupta; William A Weiss; Iska Moxon-Emre; Donald J Mabbott; Alvaro Lassaletta; Cynthia E Hawkins; Uri Tabori; James Drake; Abhaya Kulkarni; Peter Dirks; James T Rutka; Andrey Korshunov; Stefan M Pfister; Roger J Packer; Vijay Ramaswamy; Michael D Taylor Journal: Lancet Oncol Date: 2016-03-12 Impact factor: 41.316